Introduction
============

Two recent RCTs (OSCAR and OSCILLATE \[[@B1]\],\[[@B2]\]) showed that high-frequency oscillatory ventilation (HFOV) had no positive impact on mortality. We present our experience over 5 years.

Methods
=======

Adult ARDS patients who received HFOV from 2008 to 2012 were included. Demographics, illness severity and outcomes were collected retrospectively.

Results
=======

A total of 118 patients were included; 56.8% were male, mean age was 54.8 years. RRT use was 45% during admission. Vasoactive agent use and neuromuscular blockade infusion rate was 81.9 and 29.7% pre HFOV respectively. The 28-day and 6-month mortality was 61.9 and 70.3%. A total of 60.1% had less than 48 hours conventional ventilation (CV) pre HFOV. The 6-month mortality was 64.8% for this group. Patients who had over 48 hours CV pre HFOV had a 6-month mortality of 76.6%. See Table [1](#T1){ref-type="table"}.

                                     OSCAR          OSCILLATE             
  --------------------------- ------ -------------- -------------- ------ ------
  Mean APACHE II              22.0   21.8           21.7           29     29
  Mean Vt (ml/kg predicted)   8.6    8.7            8.3            7.2    7.1
  PaO~2~:FiO~2~(mmHg)         81.5   113            113            121    114
  Vasoactive agents (%)       81.9   43.5 (day 1)   44.6 (day 1)   67     63
  Hospital mortality (%)      66.1   50.1           48.4           46.9   35.2

Conclusion
==========

Mortality rates were higher than in recent trials \[[@B1]\],\[[@B2]\]. Our patients represent a more critically unwell group with lower PF ratios pre HFOV and high vasoactive and RRT use. HFOV may still have a role in the treatment of these very sick patients with treatment refractory to conventional ventilation.
